Intervention in gastro-enteropancreatic neuroendocrine tumours

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 6, 2012, Pages 855-865

  Baudin, Eric ^a   Planchard, David ^a   Scoazec, Jean Yves ^a   Guigay, Joël ^a   Dromain, Clarisse ^a   Hadoux, Julien ^a   Debaere, Thierry ^a   Elias, Dominique ^a   Ducreux, Michel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Functioning neuroendocrine tumour; Grading; Intervention; Neuroendocrine carcinoma; Neuroendocrine tumour; Poorly differentiated NET; Prognosis; TNM classification; Well differentiated NET; WHO classification

Indexed keywords

ANGIOPEPTIN; CAPECITABINE; CHLOROZOTOCIN; CISPLATIN; DIAZOXIDE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; INTERFERON; OCTREOTIDE; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BRONCHUS CARCINOID; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; DISTANT METASTASIS; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HORMONE RELEASE; HUMAN; LIVER SURGERY; LUNG CARCINOMA; LUNG SMALL CELL CANCER; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84876153473     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2013.01.008     Document Type: Review

References (86)

1. E. Baudin Gastroenteropancreatic endocrine tumors: clinical characterization before therapy Nat Clin Pract Endocrinol Metab 3 2007 228 239
2. I.M. Modlin, K. Oberg, D.C. Chung, R.T. Jensen, W.W. de Herder, and R.V. Thakker Gastroenteropancreatic neuroendocrine tumours Lancet Oncol 9 2008 61 72
3. M. Pavel, E. Baudin, A. Couvelard, E. Krenning, K. Öberg, and T. Steinmüller ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary Neuroendocrinology 95 2012 157 176
4. C.G. Moertel, L.H. Weiland, D.M. Nagorney, and M.B. Dockerty Carcinoid tumor of the appendix: treatment and prognosis N Engl J Med 317 1987 1699 1701
5. J.A. Söreide, J.A. van Heerden, G.B. Thompson, C. Schleck, D.M. Ilstrup, and M. Churchward Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients World J Surg 24 2000 1431 1436
6. B.N. Fahy, L.H. Tang, D. Klimstra, W.D. Wong, J.G. Guillem, and P.B. Paty Carcinoid of the rectum risk stratification (CaRRs): a strategy for preoperative outcome assessment Ann Surg Oncol 14 2007 1735 1743
7. L. Fischer, J. Kleeff, I. Esposito, U. Hinz, A. Zimmermann, and H. Friess Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas Br J Surg 95 2008 627 635
8. U.-F. Pape, H. Jann, J. Müller-Nordhorn, A. Bockelbrink, U. Berndt, and S.N. Willich Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors Cancer 113 2008 256 265
9. A. Ahmed, G. Turner, B. King, L. Jones, D. Culliford, and D. McCance Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study Endocr Relat Cancer 16 2009 885 894
10. G. Rindi The ENETS guidelines: the new TNM classification system Tumori 96 2010 806 809
11. A. Scarpa, W. Mantovani, P. Capelli, S. Beghelli, L. Boninsegna, and R. Bettini Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients Mod Pathol 23 2010 824 833
12. J.R. Strosberg, A. Cheema, J. Weber, G. Han, D. Coppola, and L.K. Kvols Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors J Clin Oncol 29 2011 3044 3049
13. A. Zerbi, V. Capitanio, L. Boninsegna, C. Pasquali, G. Rindi, and G. Delle Fave Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases Langenbecks Arch Surg 396 2011 313 321
14. H. Jann, S. Roll, A. Couvelard, O. Hentic, M. Pavel, and J. Müller-Nordhorn Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome Cancer 117 2011 3332 3341
15. F. Panzuto, L. Boninsegna, N. Fazio, D. Campana, M. Pia Brizzi, and G. Capurso Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression J Clin Oncol 29 2011 2372 2377
16. D. Elias, J.H. Lefevre, P. Duvillard, D. Goéré, C. Dromain, and F. Dumont Hepatic metastases from neuroendocrine tumors with a « thin slice » pathological examination: they are many more than you think Ann Surg 251 2010 307 310
17. R.T. Jensen, G. Cadiot, M.L. Brandi, W.W. de Herder, G. Kaltsas, and P. Komminoth ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes Neuroendocrinology 95 2012 98 119
18. E.T. Janson, L. Holmberg, M. Stridsberg, B. Eriksson, E. Theodorsson, and E. Wilander Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center Ann Oncol 8 1997 685 690
19. A.P. Burke, R.M. Thomas, A.M. Elsayed, and L.H. Sobin Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases Cancer 79 1997 1086 1093
20. C.Y. Lo, J.A. van Heerden, G.B. Thompson, C.S. Grant, J.A. Söreide, and W.S. Harmsen Islet cell carcinoma of the pancreas World J Surg 20 1996 878 883 [discussion 884]
21. G. Pelosi, E. Bresaola, G. Bogina, F. Pasini, S. Rodella, and P. Castelli Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables Hum Pathol 27 1996 1124 1134
22. A. Gentil Perret, J.F. Mosnier, J.P. Buono, P. Berthelot, J. Chipponi, and J.G. Balique The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors Am J Clin Pathol 109 1998 286 293
23. I. Madeira, B. Terris, M. Voss, A. Denys, A. Sauvanet, and J.F. Flejou Prognostic factors in patients with endocrine tumours of the duodenopancreatic area Gut 43 1998 422 427
24. S.N. Hochwald, S. Zee, K.C. Conlon, R. Colleoni, O. Louie, and M.F. Brennan Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups J Clin Oncol 20 2002 2633 2642
25. P. Tomassetti, D. Campana, L. Piscitelli, R. Casadei, D. Santini, and F. Nori Endocrine pancreatic tumors: factors correlated with survival Ann Oncol 16 2005 1806 1810
26. S. Ekeblad, B. Skogseid, K. Dunder, K. Oberg, and B. Eriksson Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution Clin Cancer Res 14 2008 7798 7803
27. M.H. Kulke, E.K. Bergsland, and J.C. Yao Glycemic control in patients with insulinoma treated with everolimus N Engl J Med 360 2009 195 197
28. A. Rinke, H.-H. Müller, C. Schade-Brittinger, K.-J. Klose, P. Barth, and M. Wied Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 2009 4656 4663
29. J.E. Møller, P.A. Pellikka, A.M. Bernheim, H.V. Schaff, J. Rubin, and H.M. Connolly Prognosis of carcinoid heart disease: analysis of 200 cases over two decades Circulation 112 2005 3320 3327
30. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, and E. Van Cutsem Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
31. J.-Y. Scoazec Angiogenesis in neuroendocrine tumors: therapeutic applications Neuroendocrinology 97 2013 45 56
32. M.E. Pavel, J.D. Hainsworth, E. Baudin, M. Peeters, D. Hörsch, and R.E. Winkler Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 378 2011 2005 2012
33. C. Durante, H. Boukheris, C. Dromain, P. Duvillard, S. Leboulleux, and D. Elias Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma Endocr Relat Cancer 16 2009 585 597
34. W.D. Travis, W. Rush, D.B. Flieder, R. Falk, M.V. Fleming, and A.A. Gal Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid Am J Surg Pathol 22 1998 934 944
35. G. Rindi, C. Azzoni, S. La Rosa, C. Klersy, D. Paolotti, and S. Rappel ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis Gastroenterology 116 1999 532 542
36. E. Lim, Y.K. Yap, B.L. De Stavola, A.G. Nicholson, and P. Goldstraw The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors J Thorac Cardiovasc Surg 130 2005 969 972
37. H. Asamura, T. Kameya, Y. Matsuno, M. Noguchi, H. Tada, and Y. Ishikawa Neuroendocrine neoplasms of the lung: a prognostic spectrum J Clin Oncol 24 2006 70 76
38. A. Faggiano, J.-C. Sabourin, M. Ducreux, J. Lumbroso, P. Duvillard, and S. Leboulleux Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features Cancer 110 2007 265 274
39. J.R. Strosberg, D. Coppola, D.S. Klimstra, A.T. Phan, M.H. Kulke, and G.A. Wiseman The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas Pancreas 39 2010 799 800
40. M.W. Onaitis, P.M. Kirshbom, T.Z. Hayward, F.J. Quayle, J.M. Feldman, and H.F. Seigler Gastrointestinal carcinoids: characterization by site of origin and hormone production Ann Surg 232 2000 549 556
41. P.M. Kirshbom, A.R. Kherani, M.W. Onaitis, J.M. Feldman, and D.S. Tyler Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids Surgery 124 1998 1063 1070
42. S. Musunuru, H. Chen, S. Rajpal, N. Stephani, J.C. McDermott, and K. Holen Metastatic neuroendocrine hepatic tumors: resection improves survival Arch Surg 141 2006 1000 1004 [discussion 1005]
43. O. Hentic, A. Couvelard, V. Rebours, M. Zappa, S. Dokmak, and P. Hammel Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas Endocr Relat Cancer 18 2011 51 59
44. A.S. Ho, J. Picus, M.D. Darcy, B. Tan, J.E. Gould, and T.K. Pilgram Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors AJR Am J Roentgenol 188 2007 1201 1207
45. T.E. Clancy, T.P. Sengupta, J. Paulus, F. Ahmed, M.-S. Duh, and M.H. Kulke Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors Dig Dis Sci 51 2006 877 884
46. C.G. Moertel, and J.A. Hanley Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome Cancer Clin Trials 2 1979 327 334
47. C.G. Moertel, J.A. Hanley, and L.A. Johnson Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma N Engl J Med 303 1980 1189 1194
48. P.F. Engstrom, P.T. Lavin, C.G. Moertel, E. Folsch, and H.O. Douglass Jr. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor J Clin Oncol 2 1984 1255 1259
49. R.M. Bukowski, K.G. Johnson, R.F. Peterson, R.L. Stephens, S.E. Rivkin, and B. Neilan A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study Cancer 60 1987 2891 2895
50. L. Saltz, B. Trochanowski, M. Buckley, B. Heffernan, D. Niedzwiecki, and Y. Tao Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors Cancer 72 1993 244 248
51. H.C. Weber, D.J. Venzon, J.T. Lin, V.A. Fishbein, M. Orbuch, and D.B. Strader Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study Gastroenterology 108 1995 1637 1649
52. F. Yu, D.J. Venzon, J. Serrano, S.U. Goebel, J.L. Doppman, and F. Gibril Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome J Clin Oncol 17 1999 615 630
53. J.M. Sarmiento, G. Heywood, J. Rubin, D.M. Ilstrup, D.M. Nagorney, and F.G. Que Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival J Am Coll Surg 197 2003 29 37
54. S. Faiss, U.-F. Pape, M. Böhmig, Y. Dörffel, U. Mansmann, and W. Golder Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group J Clin Oncol 21 2003 2689 2696
55. L. Kölby, G. Persson, S. Franzén, and B. Ahrén Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours Br J Surg 90 2003 687 693
56. T. Delaunoit, M. Ducreux, V. Boige, C. Dromain, J.-C. Sabourin, and P. Duvillard The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 40 2004 515 520
57. L. Dahan, F. Bonnetain, P. Rougier, J.-L. Raoul, E. Gamelin, and P.-L. Etienne Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710 Endocr Relat Cancer 16 2009 1351 1361
58. E. Raymond, L. Dahan, J.-L. Raoul, Y.-J. Bang, I. Borbath, and C. Lombard-Bohas Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 2011 501 513
59. T. Meyer, M. Caplin, N. Reed, W. Qian, S. Lao-Siriex, and G. Armstrong Treatment of advanced neuroendocrine tumors: final results of the UKINETS and NCRI randomised phase II NET01 trial ESMO Meeting Abstracts 23 2012 ix378 ix379
60. A. Vinik, E. Van Cutsem, P. Niccoli, J.-L. Raoul, Y.-J. Bang, and I. Borbath Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET) ASCO Meeting Abstracts 30 2012 4118
61. G. Rindi, R. Arnold, and F. Bosman Nomenclature and classification of neuroendocrine neoplasms of the digestive system F. Bosman, F. Carneiro, R. Hruban, N. Theise, WHO classification of tumors of the digestive system 2010 IARC Lyon
62. U.-F. Pape, A. Perren, B. Niederle, D. Gross, T. Gress, and F. Costa ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas Neuroendocrinology 95 2012 135 156
63. M. Falconi, D.K. Bartsch, B. Eriksson, G. Klöppel, J.M. Lopes, and J.M. O'Connor ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors Neuroendocrinology 95 2012 120 134
64. N. Martini, M.B. Zaman, M.S. Bains, M.E. Burt, P.M. McCormack, and V.W. Rusch Treatment and prognosis in bronchial carcinoids involving regional lymph nodes J Thorac Cardiovasc Surg 107 1994 1 6 [discussion 6-7]
65. C.F. Thomas Jr., H.D. Tazelaar, and J.R. Jett Typical and atypical pulmonary carcinoids: outcome in patients presenting with regional lymph node involvement Chest 119 2001 1143 1150
66. M. Mezzetti, F. Raveglia, T. Panigalli, L. Giuliani, F. Lo Giudice, and S. Meda Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification Ann Thorac Surg 76 2003 1838 1842
67. G. Cardillo, F. Sera, M. Di Martino, P. Graziano, R. Giunti, and L. Carbone Bronchial carcinoid tumors: nodal status and long-term survival after resection Ann Thorac Surg 77 2004 1781 1785
68. M. García-Yuste, J.M. Matilla, A. Cueto, J.M.R. Paniagua, G. Ramos, and M.A. Cañizares Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung Eur J Cardiothorac Surg 31 2007 192 197
69. S. La Rosa, F. Inzani, A. Vanoli, C. Klersy, L. Dainese, and G. Rindi Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms Hum Pathol 42 2011 1373 1384
70. G. Delle Fave, D.J. Kwekkeboom, E. Van Cutsem, G. Rindi, B. Kos-Kudla, and U. Knigge ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms Neuroendocrinology 95 2012 74 87
71. J.R. Strosberg, R.L. Fine, J. Choi, A. Nasir, D. Coppola, and D.-T. Chen First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas Cancer 117 2011 268 275
72. G. Rindi, M. Falconi, C. Klersy, L. Albarello, L. Boninsegna, and M.W. Buchler TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study J Natl Cancer Inst 104 2012 764 777
73. R.S. Greenberg, D.A. Baumgarten, W.S. Clark, P. Isacson, and K. McKeen Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors Cancer 60 1987 2476 2483
74. F. Panzuto, S. Nasoni, M. Falconi, V.D. Corleto, G. Capurso, and S. Cassetta Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization Endocr Relat Cancer 12 2005 1083 1092
75. M.B. Beasley, F.B. Thunnissen, E. Brambilla, P. Hasleton, R. Steele, and S.P. Hammar Pulmonary atypical carcinoid: predictors of survival in 106 cases Hum Pathol 31 2000 1255 1265
76. M.A. Kouvaraki, J.A. Ajani, P. Hoff, R. Wolff, D.B. Evans, and R. Lozano Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas J Clin Oncol 22 2004 4762 4771
77. J.C. Yao, C. Lombard-Bohas, E. Baudin, L.K. Kvols, P. Rougier, and P. Ruszniewski Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial J Clin Oncol 28 2010 69 76
78. C.G. Moertel, M. Lefkopoulo, S. Lipsitz, R.G. Hahn, and D. Klaassen Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma N Engl J Med 326 1992 519 523
79. W. Sun, S. Lipsitz, P. Catalano, J.A. Mailliard, and D.G. Haller Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281 J Clin Oncol 23 2005 4897 4904
80. R. Arnold, A. Rinke, K.-J. Klose, H.-H. Müller, M. Wied, and K. Zamzow Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial Clin Gastroenterol Hepatol 3 2005 761 771
81. F.G. Que, D.M. Nagorney, K.P. Batts, L.J. Linz, and L.K. Kvols Hepatic resection for metastatic neuroendocrine carcinomas Am J Surg 169 1995 36 42 [discussion 42-43]
82. D. Elias, P. Lasser, M. Ducreux, P. Duvillard, J.-F. Ouellet, and C. Dromain Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study Surgery 133 2003 375 382
83. S.C. Mayo, M.C. de Jong, M. Bloomston, C. Pulitano, B.M. Clary, and S.K. Reddy Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis Ann Surg Oncol 18 2011 3657 3665
84. D.L. Bushnell Jr., T.M. O'Dorisio, M.S. O'Dorisio, Y. Menda, R.J. Hicks, and E. Van Cutsem 90Y-edotreotide for metastatic carcinoid refractory to octreotide J Clin Oncol 28 2010 1652 1659
85. R.M. Bukowski, C. Tangen, R. Lee, J.S. Macdonald, A.B. Einstein Jr., and R. Peterson Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study J Clin Oncol 10 1992 1914 1918
86. R.K. Ramanathan, A. Cnaan, R.G. Hahn, P.P. Carbone, and D.G. Haller Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282 Ann Oncol 12 2001 1139 1143